30.00
+5.49%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medincell
Its shares trade on Euronext Paris under the ticker MEDCL.PA. It has been listed since 8 October 2018. In the fiscal year to 31 March 2026, it reported revenue of €19.5m and a net loss of €31.3m. At that date it held total assets of €108.1m and shareholders' equity of €3.1m.
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Oct 2018
- Employees
- 138
- Website
- medincell.com ↗
Leadership
Pay as last reported
- Mr. Philippe GuyNon-Executive Chairman of the Board, since 2010€70,056
- Mr. Christophe DouatChief Executive Officer, Executive Director, since 2014€489,873
- Ms. Elisabeth KoganNon-Executive Independent Vice Chairman of the Board€41,000
- Mr. Stephane PosticChief Financial Officer
- Mr. Philippe MoyenChief Operating Officer
- Mr. Franck PouzacheChief People Officer€119,058
- Ms. Julie AlimiGeneral Counsel, Chief Corporate Development Officer
- Mr. Sebastien EnaultChief Business Officer
- Mr. Adolfo Lopez-NoriegaHead - Research and Development
- Dr. Richard MalamutChief Medical Officer
- Dr. Charles KunschIndependent Director
- Dr. Sharon MatesIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medincell SA has several key strengths which contribute to its success in the market. One of its main strengths is its innovative drug delivery technology, which allows for the controlled release of medications over extended periods of time. This technology provides significant advantages over traditional drug delivery methods, such as increased patient compliance and reduced side effects.
- In addition, Medincell SA has a strong intellectual property portfolio, with numerous patents protecting its drug delivery technology. This provides the company with a competitive advantage and helps to ensure its long-term success in the market.
Weaknesses
- Despite its strengths, Medincell SA also faces certain weaknesses that could potentially hinder its growth. One of the main weaknesses is the high cost of developing and commercializing its drug delivery technology. This can be a barrier to entry for some potential partners or investors.
- Furthermore, Medincell SA's success heavily relies on the successful development and regulatory approval of its pipeline products. Any delay or failure in these processes can significantly impact the company's performance.
Opportunities
- Medincell SA operates in a market with vast opportunities. The growing demand for improved drug delivery systems, especially in chronic disease management, presents a significant market opportunity for the company. Medincell SA's innovative technology positions it well to capture a substantial market share.
- Additionally, strategic collaborations and partnerships with pharmaceutical companies could provide Medincell SA with access to broader distribution networks and resources, allowing for faster commercialization of its products.
Threats
- Medincell SA faces several potential threats that could impact its business. One major threat is the presence of competitors in the drug delivery technology space. With the growing interest in this field, new entrants may emerge, posing a challenge to Medincell SA's market position.
- Moreover, regulatory and compliance requirements in the healthcare industry can be complex and time-consuming. Failure to meet these requirements could lead to delays in product approvals and commercialization, reducing the company's competitive advantage.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.